Equillium (EQ) Stock Price, News & Analysis

Company Overview

Equillium, Inc. is a clinical-stage biotechnology company focused on developing therapies for severe autoimmune and inflammatory diseases. The company’s approach centers on modulating immune pathways involved in disease progression, with the goal of addressing conditions that have limited treatment options.

Equillium’s lead product candidate is itolizumab, a monoclonal antibody that targets CD6, an immune-cell receptor involved in the regulation of T-cell activity. The company is evaluating itolizumab in immune-mediated conditions, including acute graft-versus-host disease and lupus nephritis. Equillium also has an earlier-stage pipeline that includes peptide-based therapies designed to inhibit inflammatory pathways such as interleukin-17.

Founded in 2017 and headquartered in San Diego, California, Equillium has built its development programs through internal research and strategic collaborations, including an agreement with Biocon for rights related to itolizumab. As a clinical-stage company, Equillium’s activities are primarily focused on research, clinical development and advancing its pipeline toward potential regulatory approval.

Key Stats

• Today's Range: $1.30 to $1.38
• 50-Day Range: $1.30 to $2.56
• 52-Week Range: $0.76 to $3.54
• Volume: 263,692 shs
• Average Volume: 760,050 shs
• Market Capitalization: $82.43 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.57
• Consensus Rating: Moderate Buy

Equillium Stock Analysis - MarketRank™

Equillium scored higher than 50% of companies evaluated by MarketBeat, and ranked 550th out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Equillium has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 2 strong buy ratings, 7 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Equillium has a consensus price target of $7.57, representing about 482.4% upside from its current price of $1.30.

Amount of Analyst Coverage

Equillium has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Equillium are expected to decrease in the coming year, from ($0.21) to ($0.24) per share.

Price to Book Value per Share Ratio

Equillium has a P/B Ratio of 2.77. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.64% of the float of Equillium has been sold short.

Short Interest Ratio / Days to Cover

Equillium has a short interest ratio ("days to cover") of 5.99.

Change versus previous month

Short interest in Equillium has recently increased by 0.74%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Equillium does not currently pay a dividend.

Dividend Growth

Equillium does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.81

News Sentiment

Equillium has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Equillium this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for EQ on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

MarketBeat Follows

2 people have added Equillium to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Equillium insiders have not sold or bought any company stock.

Percentage Held by Insiders

17.84% of the stock of Equillium is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

27.05% of the stock of Equillium is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/14/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:EQ
• CIK: 1746466
• Web: equilliumbio.com
• Phone: (858) 412-5302
• Fax: N/A
• Employees: 14
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Equillium: $7.57
• High Price Target: $12.00
• Low Price Target: $5.00
• Potential Upside/Downside: +482.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.91
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.20)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$22.40 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -41.15%
• Return on Assets: -38.29%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 23.40
• Quick Ratio: 23.40

Sales & Book Value

• Annual Sales: $41.10 million
• Price / Sales: 2.01
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.47 per share
• Price / Book: 2.77

Miscellaneous

• Outstanding Shares: 63,410,000
• Free Float: 52,096,000
• Market Cap: $82.43 million
• Optionable: Not Optionable
• Beta: 1.93